Targeting CD38 with Isa induces immunomodulation, alleviating immunosuppression by inhibiting proliferation and migration of regulatory T cells and enhancing anti-MM immunity mediated by CD8+ T cells and NK cells. Here, CD38 is linked to Miyoshi myopathy.